Lymphoma Treatment in India: Hodgkin & Non-Hodgkin, Costs & CAR-T 2026
Lymphoma Treatment in India: Hodgkin & Non-Hodgkin, Costs & CAR-T 2026
Lymphoma is a cancer of the lymphatic system, and it is one of the most treatable of all cancers when diagnosed and managed correctly. India has established itself as a leading destination for lymphoma treatment — with experienced haematologists, access to modern chemotherapy protocols, state-of-the-art PET-CT monitoring, and now CAR-T cell therapy at a fraction of Western costs.
This guide covers the treatment landscape for both Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), costs versus the USA, protocol availability, and how African patients can access care.
Hodgkin vs Non-Hodgkin Lymphoma: Key Differences
| Feature | Hodgkin Lymphoma (HL) | Non-Hodgkin Lymphoma (NHL) |
|---|---|---|
| Prevalence | Less common (~10% of lymphomas) | More common (~90%) |
| Age profile | Bimodal: 20s and 60s+ | Any age, more common in elderly |
| Histology | Reed-Sternberg cells | Multiple subtypes (DLBCL, follicular, mantle cell, Burkitt's, MALT, etc.) |
| Curability | High — most stages curable | Depends heavily on subtype |
| Standard treatment | ABVD or BEACOPP; radiotherapy | Depends on subtype; typically R-CHOP or variant |
First-Line Treatment Protocols in India
Hodgkin Lymphoma:
ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine):
The standard first-line regimen for classical Hodgkin lymphoma worldwide. 2–6 cycles depending on stage. Indian hospitals follow NCCN guidelines precisely. Cost per cycle in India: USD 600–1,200.
BEACOPP escalated:
Used for advanced-stage (III–IV) Hodgkin lymphoma with poor prognostic features. More toxic than ABVD but superior progression-free survival in high-risk cases. Available at major Indian cancer centres.
Diffuse Large B-Cell Lymphoma (DLBCL — most common NHL):
R-CHOP (Rituximab + CHOP):
Standard of care for DLBCL. 6 cycles, 21-day intervals. Indian biosimilar rituximab (Maball, Reditux) reduces cost by 70–80% versus branded Rituxan. Cost per cycle in India: USD 1,500–3,500 (including rituximab).
Pola-R-CHP (Polatuzumab vedotin + R-CHP):
Newer standard replacing R-CHOP for some DLBCL patients. Available at major centres. Polatuzumab available in India at select hospitals.
Salvage Regimens for Relapsed/Refractory Lymphoma
When first-line therapy fails, salvage chemotherapy is administered before high-dose therapy and stem cell transplant:
ICE (Ifosfamide, Carboplatin, Etoposide):
Standard NHL salvage regimen. Cost per cycle in India: USD 2,000–4,000.
DHAP / GDP:
Alternative salvage regimens for both HL and NHL. Available at all major Indian haematology centres.
High-dose therapy + ASCT:
After response to salvage, autologous stem cell transplant consolidates remission. Cost in India: USD 18,000–28,000 (vs USD 120,000–200,000 in the USA).
CAR-T Cell Therapy in India: NexCAR19
India's approval of NexCAR19 in 2024 was a landmark in global oncology. Developed by ImmunoACT in collaboration with IIT Bombay and Tata Memorial Hospital, NexCAR19 is a CD19-directed CAR-T therapy for:
- Relapsed/refractory B-cell lymphoma (after 2+ prior lines)
- Relapsed/refractory B-cell ALL
Why it matters:
Western CAR-T products (Kymriah, Yescarta, Breyanzi) cost USD 350,000–500,000 in the USA. NexCAR19 in India costs approximately USD 30,000–50,000 — a 90% price reduction for essentially equivalent technology.
Availability:
- Tata Memorial Hospital, Mumbai (highest volume)
- Apollo Cancer Centre, Chennai and Delhi
- Artemis Hospital, Gurgaon
Eligibility requires:
- Confirmed relapse/refractory status after ≥2 prior lines of therapy
- Adequate organ function
- CD19+ tumour (confirmed on biopsy)
- Performance status ECOG 0–1
PET-CT Monitoring: India's Cost Advantage
PET-CT is indispensable in lymphoma management — for initial staging, interim response assessment, and end-of-treatment evaluation. In the USA, one PET-CT scan costs USD 5,000–10,000. In India:
| Scan | India (USD) | USA (USD) | UK (GBP equivalent USD) |
|---|---|---|---|
| FDG PET-CT (whole body) | 400–700 | 5,000–10,000 | 3,000–6,000 |
| Interim PET-CT (cycle 2–4) | 400–700 | 5,000–10,000 | 3,000–6,000 |
For a 6-cycle R-CHOP protocol requiring 3 PET-CT scans, India saves USD 13,000–28,000 on scans alone.
Top Hospitals for Lymphoma in India
Tata Memorial Hospital, Mumbai
India's national cancer centre. Largest lymphoma caseload nationally. Public hospital — costs are the lowest nationally. Department of Medical Oncology and BMT Unit are excellent. International patients accepted with medical visa.
Apollo Cancer Centres (Delhi, Chennai, Hyderabad)
Full lymphoma programme including CAR-T at Chennai. Excellent international patient infrastructure. Shorter waiting times than Tata Memorial.
Rajiv Gandhi Cancer Institute and Research Centre, Delhi
Strong haematology-oncology department. High NHL and HL case volume. Full BMT capability.
Fortis Memorial Research Institute, Gurgaon
Experienced haematology team. Significant international patient caseload from Africa.
Kidwai Memorial Institute, Bangalore
Leading public cancer centre for southern India. Exceptional expertise at government hospital costs.
Costs Comparison: India vs USA for Full Lymphoma Treatment
| Treatment | India (USD) | USA (USD) | India Saving |
|---|---|---|---|
| 6 cycles R-CHOP | 9,000–18,000 | 60,000–100,000 | ~80–85% |
| 6 cycles ABVD | 4,000–8,000 | 30,000–60,000 | ~85% |
| 3 PET-CT scans | 1,200–2,100 | 15,000–30,000 | ~93% |
| ASCT post-salvage | 18,000–28,000 | 120,000–200,000 | ~85% |
| CAR-T therapy | 30,000–50,000 | 350,000–500,000 | ~90% |
What to Bring: Medical Records for Lymphoma Assessment
- Biopsy report with full histopathological classification and IHC panel
- PET-CT or CT staging report and images (on CD or DICOM files)
- Full blood count, LFT, renal function, LDH, uric acid, beta-2 microglobulin
- HIV test result (required before lymphoma treatment)
- Bone marrow biopsy report (if done)
- Previous treatment records (if relapsed/refractory)
Starting Your Lymphoma Treatment in India
Lymphoma treatment in India offers a combination that few countries match: specialist haematologists trained at leading global centres, access to the same drugs used in the USA and Europe (at 70–90% lower cost), and now CAR-T therapy at globally accessible pricing.
Share your biopsy report with Arodya for a free specialist review →
We'll have your case reviewed by a senior haematologist, provide a treatment plan and cost breakdown, and coordinate your full journey from diagnosis to remission.
